Tacrolimus immediate-release formulations are authorised for use in preventing organ rejection in adult and paediatric patients undergoing allogeneic liver, kidney, heart, or lung transplants when used in combination with other immunosuppressant. When paired with other immunosuppressant, tacrolimus extended-release formulations are approved for the prevention of organ rejection in adult and paediatric patients receiving kidney transplants, and they may be used in patients who have switched from tacrolimus immediate-release formulations.

The demand for Tacrolimus Market is rising due to the increasing number of organ transplant surgeries, the rising prevalence of autoimmune diseases, and the availability of new formulations of the medication. The tacrolimus market is expected to continue to grow in the coming years, with capsules, organ transplantation, hospital pharmacies, and North America expected to hold the largest shares of the market.

Read More- https://cmi-latestreportorientedblogs.blogspot.com/2023/04/the-global-tacrolimus-market-is.html